Boehringer Ingelheim invites scientists to submit proposals containing an in vivo testable hypothesis using its oral BCL6 degrader.
Boehringer Ingelheim will share the unprecedented, potent and selective orally bioavailable BCL6 degrader BI-1136 which is suited for both in vitro and in vivo experiments for collaborative research on novel disease indications. BI-1136 potently degrades human and mouse BCL6. Funding of up to 200.000 € will be available upon request and shall be outlined in the application.
Deadline: July 31, 2019, 23:59 pm PST
More information: https://opnme.com/molecules/oral-bcl6-degrader